A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events

Anne-Line Couillerot-Peyrondet (), Cléa Sambuc, Yoël Sainsaulieu, Cécile Couchoud and Isabelle Bongiovanni-Delarozière
Additional contact information
Anne-Line Couillerot-Peyrondet: Service évaluation économique et santé publique. Haute Autorité de Santé
Cléa Sambuc: Service évaluation économique et santé publique. Haute Autorité de Santé
Yoël Sainsaulieu: Pôle Organisation et Financement des Activités de Soins. Agence de la biomédecine
Cécile Couchoud: REIN registry. Agence de la biomédecine
Isabelle Bongiovanni-Delarozière: Service évaluation économique et santé publique. Haute Autorité de Santé

The European Journal of Health Economics, 2017, vol. 18, issue 4, No 6, 459-469

Abstract: Abstract Objectives In the current pressured economic context, and to continue to treat the growing number of patients with high-quality standards, the first step is to have a better understanding of the costs related to end-stage renal disease (ESRD) treatment according to various renal replacement therapy, age, diabetes status, and clinical events. Methods In order to estimate the direct costs of all adult ESRD patients, according to (RRT) modality, patient condition, and clinical events, data from the French national health insurance funds were used. Results The mean monthly costs for the 47,862 stable prevalent patients (73 % of the population) varied substantially according to treatment modality (from 7300€ for in-center hemodialysis to 1100€ for a functioning renal graft) and to clinical event (8300€ for the first month of dialysis, 11,000€ for the last month before death, 22,800€ for the first month after renal transplantation). Mean monthly costs varied according to diabetic status and to age to a lesser extent. Conclusions These results demonstrate, for the first time in France and in Europe, the importance of a dynamic view of renal care and the bias likely when comparing treatments in cross-sectional studies.

Keywords: End-stage renal disease; costs; Renal replacement therapy; Diabetes; Age (search for similar items in EconPapers)
Date: 2017
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-016-0801-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:18:y:2017:i:4:d:10.1007_s10198-016-0801-6

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-016-0801-6

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().